Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Genmab A/S's quarterly P/E stands at 11.8x, up 277.4% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 663.2% YoY to 9.1x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 14.44 | 11.80 | 1.51 | 15.79 | 0.87 | 3.13 | 2.90 | 3.70 | 8.21 | 2.73 | 4.61 | 29.50 | 12.04 |
| — | +277.4% | -47.8% | +326.6% | -89.4% | +14.5% | -37.2% | -87.5% | -31.8% | +33.2% | +63.0% | +131.6% | +31.5% | |
| P/S Ratio | 5.02 | 4.66 | 0.55 | 4.38 | 0.52 | 0.71 | 5.23 | 8.14 | 1.12 | 1.23 | 1.50 | 2.19 | 1.36 |
| — | +552.4% | -89.6% | -46.2% | -53.6% | -42.1% | +248.7% | +271.3% | -17.9% | -4.9% | -11.5% | -22.1% | -45.4% | |
| P/B Ratio | 3.09 | 3.31 | 0.38 | 0.37 | 0.36 | 0.50 | 0.53 | 0.60 | 0.66 | 0.75 | 0.87 | 0.91 | 1.03 |
| — | +568.0% | -27.6% | -38.3% | -44.9% | -33.6% | -39.5% | -33.9% | -35.4% | -6.0% | -0.6% | -13.0% | -12.9% | |
| P/FCF | 14.24 | 8.91 | 9.72 | 1.79 | 11.18 | 1.99 | 18.96 | 22.84 | 3.26 | 3.00 | 18.46 | 1.98 | 24.31 |
| — | +347.4% | -48.8% | -92.2% | +242.6% | -33.5% | +2.7% | +1050.5% | -86.6% | +6.7% | +206.8% | -82.4% | -35.7% | |
| EV / EBITDA | 13.94 | 9.13 | 0.58 | 6.43 | 0.51 | 1.20 | 12.99 | 11.59 | 0.99 | 1.38 | 2.46 | 7.11 | 1.78 |
| — | +663.2% | -95.5% | -44.5% | -48.8% | -13.2% | +428.9% | +62.9% | -44.4% | -3.9% | +5.0% | +7.7% | -64.9% | |
| EV / EBIT | 14.80 | 8.98 | 0.51 | 5.26 | 0.50 | 1.23 | 10.48 | 5.91 | 1.84 | 0.91 | 2.55 | 8.03 | 1.79 |
| — | +627.3% | -95.2% | -10.9% | -72.6% | +35.6% | +311.4% | -26.5% | +2.7% | -38.5% | +3.7% | +30.1% | -60.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Genmab A/S's operating margin was 44.9% in Q3 2025, up 6.0 pp QoQ and up 7.0 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 35.9% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.4% | 94.3% | 93.8% | 94.1% | 94.8% | 95.1% | 96.4% | 95.5% | 97.3% | 98.3% | 99.5% | 100.0% | 100.0% |
| — | -0.8% | -2.7% | -1.5% | -2.6% | -3.3% | -3.1% | -4.5% | -2.7% | -1.7% | -0.5% | 0.0% | 0.0% | |
| Operating Margin | 31.1% | 44.9% | 38.9% | 26.3% | 33.5% | 37.9% | 30.3% | 19.2% | 35.7% | 35.8% | 35.2% | 14.7% | 50.1% |
| — | +18.4% | +28.5% | +36.7% | -6.1% | +6.1% | -14.0% | +30.7% | -28.8% | -24.3% | -10.7% | -39.3% | +62.3% | |
| Net Margin | 36.4% | 39.2% | 36.3% | 27.3% | 59.7% | 22.9% | 26.1% | 31.8% | 13.7% | 44.7% | 32.0% | 7.4% | 10.0% |
| — | +71.7% | +39.4% | -14.3% | +336.3% | -48.8% | -18.6% | +329.7% | +36.7% | -29.3% | -46.5% | -66.2% | -63.4% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 23.0% | 2.0% | 6.3% | 0.6% | 11.2% | 4.0% | 0.6% | 0.6% | 2.0% | 7.0% | 4.8% | 0.8% | 1.9% |
| — | -49.4% | +890.7% | -7.4% | +449.1% | -42.7% | -86.6% | -22.3% | +7.1% | -30.4% | -40.4% | -62.8% | -42.1% | |
| ROA | 19.3% | 1.7% | 5.2% | 0.4% | 9.0% | 3.2% | 0.5% | 0.5% | 1.8% | 6.3% | 4.3% | 0.7% | 1.7% |
| — | -48.3% | +864.0% | -15.8% | +395.7% | -48.3% | -87.4% | -23.1% | +7.3% | -29.5% | -40.7% | -63.0% | -42.6% | |
| ROIC | 22.2% | 2.3% | 6.5% | 0.5% | 6.0% | 5.8% | 0.8% | 0.5% | 7.1% | 7.0% | 6.4% | 1.9% | 11.1% |
| — | -61.1% | +753.7% | +8.7% | -16.5% | -16.5% | -88.1% | -74.2% | -35.6% | -22.6% | +0.4% | -33.3% | +143.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Genmab A/S's Debt/EBITDA ratio is 0.3x, down from 0.4x last quarter — comfortably within a safe range. The current ratio has improved 16.7% YoY to 6.03x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
| — | -20.1% | -15.2% | -10.2% | +15.1% | +21.3% | +17.8% | +1.9% | +11.3% | +8.0% | +7.8% | +66.5% | +14.3% | |
| Debt / EBITDA | 0.14 | 0.30 | 0.39 | 4.60 | 0.46 | 0.45 | 4.08 | 7.83 | 0.45 | 0.45 | 0.53 | 1.76 | 0.23 |
| — | -34.0% | -90.3% | -41.3% | +2.8% | +0.7% | +672.6% | +344.8% | +96.0% | +42.0% | +8.9% | +143.7% | -53.5% | |
| Current Ratio | 5.25 | 6.03 | 6.22 | 6.22 | 5.25 | 5.17 | 5.03 | 12.46 | 13.34 | 11.38 | 14.93 | 14.44 | 15.48 |
| — | +16.7% | +23.7% | -50.1% | -60.7% | -54.6% | -66.3% | -13.7% | -13.8% | +18.3% | +13.8% | -16.6% | +6.8% | |
| Quick Ratio | 5.24 | 6.01 | 6.20 | 6.20 | 5.24 | 5.15 | 5.02 | 12.42 | 13.32 | 11.36 | 14.90 | 14.44 | 15.48 |
| — | +16.7% | +23.5% | -50.1% | -60.7% | -54.6% | -66.3% | -14.0% | -14.0% | +18.1% | +13.6% | -16.6% | +6.8% | |
| Interest Coverage | 55.86 | 153.00 | 40.00 | 37.60 | 40.00 | 116.78 | 12.42 | 29.00 | 278.33 | 210.63 | 209.71 | 69.50 | 515.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying GMAB stock.
Genmab A/S's current P/E is 14.4x. The average P/E over the last 4 quarters is 7.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Genmab A/S's current operating margin is 31.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Genmab A/S's business trajectory between earnings reports.